» Articles » PMID: 39025870

Change is in the Air: Key Questions on the 'Treatable Traits' Model for Chronic Airway Diseases in Primary Care

Overview
Authors
Affiliations
Soon will be listed here.
Abstract

Despite great advancements in the treatment of chronic airway diseases, improvements in morbidity and mortality have stalled in recent years. Asthma and chronic obstructive pulmonary disease are complex and heterogeneous diseases that require tailored management based on individual patient characteristics and needs. The Treatable Traits (TTs) approach aims to personalise and improve patient care through the identification and targeting of clinically relevant and modifiable pulmonary, extra-pulmonary and behavioural traits. In this article, we outline the rationale for TTs-based management and provide practical guidance for its application in primary care. To aid implementation, seven potential 'prime' traits are proposed: airflow obstruction, eosinophilic inflammation, adherence, inhaler technique, smoking, low body mass index/obesity and anxiety and depression-selected for their prevalence, recognisability and feasibility of use. Some of the key questions among healthcare professionals, that may be roadblocks to widespread application of a TTs model of care, are also addressed.

References
1.
Korevaar D, Damen J, Heus P, Moen M, Spijker R, van Veen I . Effectiveness of FeNO-guided treatment in adult asthma patients: A systematic review and meta-analysis. Clin Exp Allergy. 2023; 53(8):798-808. DOI: 10.1111/cea.14359. View

2.
Humenberger M, Horner A, Labek A, Kaiser B, Frechinger R, Brock C . Adherence to inhaled therapy and its impact on chronic obstructive pulmonary disease (COPD). BMC Pulm Med. 2018; 18(1):163. PMC: 6194635. DOI: 10.1186/s12890-018-0724-3. View

3.
Singh D, Agusti A, Martinez F, Papi A, Pavord I, Wedzicha J . Blood Eosinophils and Chronic Obstructive Pulmonary Disease: A Global Initiative for Chronic Obstructive Lung Disease Science Committee 2022 Review. Am J Respir Crit Care Med. 2022; 206(1):17-24. DOI: 10.1164/rccm.202201-0209PP. View

4.
Barry L, Sweeney J, ONeill C, Price D, Heaney L . The cost of systemic corticosteroid-induced morbidity in severe asthma: a health economic analysis. Respir Res. 2017; 18(1):129. PMC: 5485660. DOI: 10.1186/s12931-017-0614-x. View

5.
Lee L, Bailes Z, Barnes N, Boulet L, Edwards D, Fowler A . Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial. Lancet Respir Med. 2020; 9(1):69-84. DOI: 10.1016/S2213-2600(20)30389-1. View